1447325-52-1

Basic information

• Product Name: (R)-3-(4-bromo-3,5-dimethyl-phenoxy)-tetrahydro-furan
• Synonyms: (R)-3-(4-bromo-3,5-dimethyl-phenoxy)-tetrahydro-furan
• CAS NO: 1447325-52-1
• Molecular Weight: 271.154
• Mol File: 1447325-52-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (R)-3-(4-bromo-3,5-dimethyl-phenoxy)-tetrahydro-furan(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(4-bromo-3,5-dimethyl-phenoxy)-tetrahydro-furan(1447325-52-1)
• EPA Substance Registry System: (R)-3-(4-bromo-3,5-dimethyl-phenoxy)-tetrahydro-furan(1447325-52-1)

Safety Data

• Hazardous Substances Data: 1447325-52-1(Hazardous Substances Data)

Upstream product

• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 86087-23-2 (S)-3-hydroxytetyrahydrofurane 
• 112052-11-6 toluene-4-sulfonic acid (S)-(tetrahydrofuran-3-yl)ester 

Relevant articles and documents

POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutic agents, especially the GPR40 agonist and in preparation of drugs for treating diseases such as diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description.

NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS

The present invention relates to compounds of general formula I, (I) wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.